These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38843617)

  • 41. Pathway-specific dysregulation of striatal excitatory synapses by LRRK2 mutations.
    Chen C; Soto G; Dumrongprechachan V; Bannon N; Kang S; Kozorovitskiy Y; Parisiadou L
    Elife; 2020 Oct; 9():. PubMed ID: 33006315
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain.
    Xu E; Boddu R; Abdelmotilib HA; Sokratian A; Kelly K; Liu Z; Bryant N; Chandra S; Carlisle SM; Lefkowitz EJ; Harms AS; Benveniste EN; Yacoubian TA; Volpicelli-Daley LA; Standaert DG; West AB
    Mol Neurodegener; 2022 Jan; 17(1):7. PubMed ID: 35012605
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Methylation of α-synuclein and leucine-rich repeat kinase 2 in leukocyte DNA of Parkinson's disease patients.
    Tan YY; Wu L; Zhao ZB; Wang Y; Xiao Q; Liu J; Wang G; Ma JF; Chen SD
    Parkinsonism Relat Disord; 2014 Mar; 20(3):308-13. PubMed ID: 24398085
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pathogenic LRRK2 requires secondary factors to induce cellular toxicity.
    Lobbestael E; Van den Haute C; Macchi F; Taymans JM; Baekelandt V
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32975566
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Brain and Cerebrospinal Fluid α-Synuclein Real-Time Quaking-Induced Conversion Identifies Lewy Body Pathology in LRRK2-PD.
    Garrido A; Fairfoul G; Tolosa E; Marti MJ; Ezquerra M; Green AJE
    Mov Disord; 2023 Feb; 38(2):333-338. PubMed ID: 36471633
    [TBL] [Abstract][Full Text] [Related]  

  • 46. LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease.
    Alegre-Abarrategui J; Ansorge O; Esiri M; Wade-Martins R
    Neuropathol Appl Neurobiol; 2008 Jun; 34(3):272-83. PubMed ID: 17971075
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation.
    Giordana MT; D'Agostino C; Albani G; Mauro A; Di Fonzo A; Antonini A; Bonifati V
    Mov Disord; 2007 Jan; 22(2):275-8. PubMed ID: 17149743
    [TBL] [Abstract][Full Text] [Related]  

  • 48. LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study.
    Sharma S; Bandopadhyay R; Lashley T; Renton AE; Kingsbury AE; Kumaran R; Kallis C; Vilariño-Güell C; O'Sullivan SS; Lees AJ; Revesz T; Wood NW; Holton JL
    Neuropathol Appl Neurobiol; 2011 Dec; 37(7):777-90. PubMed ID: 21696411
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Age at onset in LRRK2-associated PD is modified by SNCA variants.
    Botta-Orfila T; Ezquerra M; Pastor P; Fernández-Santiago R; Pont-Sunyer C; Compta Y; Lorenzo-Betancor O; Samaranch L; Martí MJ; Valldeoriola F; Calopa M; Fernández M; Aguilar M; de Fabregas O; Hernández-Vara J; Tolosa E
    J Mol Neurosci; 2012 Sep; 48(1):245-7. PubMed ID: 22669510
    [TBL] [Abstract][Full Text] [Related]  

  • 50. First neuropathological description of a patient with Parkinson's disease and LRRK2 p.N1437H mutation.
    Puschmann A; Englund E; Ross OA; Vilariño-Güell C; Lincoln SJ; Kachergus JM; Cobb SA; Törnqvist AL; Rehncrona S; Widner H; Wszolek ZK; Farrer MJ; Nilsson C
    Parkinsonism Relat Disord; 2012 May; 18(4):332-8. PubMed ID: 22154298
    [TBL] [Abstract][Full Text] [Related]  

  • 51. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
    Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
    Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson's Disease and G2019S LRRK2 Cohorts.
    Padmanabhan S; Lanz TA; Gorman D; Wolfe M; Joyce A; Cabrera C; Lawrence-Henderson R; Levers N; Joshi N; Ma TC; Liong C; Narayan S; Alcalay RN; Hutten SJ; Baptista MAS; Merchant K
    J Parkinsons Dis; 2020; 10(2):623-629. PubMed ID: 32007961
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation.
    Isaias IU; Benti R; Goldwurm S; Zini M; Cilia R; Gerundini P; Di Fonzo A; Bonifati V; Pezzoli G; Antonini A
    Mov Disord; 2006 Aug; 21(8):1144-7. PubMed ID: 16671078
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications.
    Qing H; Wong W; McGeer EG; McGeer PL
    Biochem Biophys Res Commun; 2009 Sep; 387(1):149-52. PubMed ID: 19576176
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons.
    López de Maturana R; Lang V; Zubiarrain A; Sousa A; Vázquez N; Gorostidi A; Águila J; López de Munain A; Rodríguez M; Sánchez-Pernaute R
    J Neuroinflammation; 2016 Nov; 13(1):295. PubMed ID: 27863501
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Altered intrinsic brain functional connectivity in drug-naïve Parkinson's disease patients with LRRK2 mutations.
    Hou Y; Luo C; Yang J; Ou R; Song W; Chen Y; Gong Q; Shang H
    Neurosci Lett; 2018 May; 675():145-151. PubMed ID: 29567424
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies.
    Perry G; Zhu X; Babar AK; Siedlak SL; Yang Q; Ito G; Iwatsubo T; Smith MA; Chen SG
    Neurodegener Dis; 2008; 5(3-4):222-4. PubMed ID: 18322396
    [TBL] [Abstract][Full Text] [Related]  

  • 58. LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice.
    Henderson MX; Sengupta M; McGeary I; Zhang B; Olufemi MF; Brown H; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2019 Feb; 7(1):28. PubMed ID: 30808409
    [TBL] [Abstract][Full Text] [Related]  

  • 59. G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.
    Volpicelli-Daley LA; Abdelmotilib H; Liu Z; Stoyka L; Daher JP; Milnerwood AJ; Unni VK; Hirst WD; Yue Z; Zhao HT; Fraser K; Kennedy RE; West AB
    J Neurosci; 2016 Jul; 36(28):7415-27. PubMed ID: 27413152
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease.
    Cresto N; Gardier C; Gubinelli F; Gaillard MC; Liot G; West AB; Brouillet E
    Eur J Neurosci; 2019 Feb; 49(3):339-363. PubMed ID: 30269383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.